Clinical Trials
55 trialsNCT00936390 2026-03-06
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT01546987 2026-03-06
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT05701007 2026-01-29
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Pfizer
Completed
NCT03056755 2026-01-13
BYLieve
Novartis
Phase 2 Completed
NCT03822468 2025-10-16
AMALEE
Novartis
Phase 2 Completed
NCT02003209 2025-08-08
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT02430480 2025-07-16
Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00328614 2025-05-16
Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer
Thomas Jefferson University
Phase 1 Completed
NCT02278185 2025-05-11
Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
University of Colorado, Denver
Phase 2 Completed
NCT03839823 2024-10-09
RIGHT Choice
Novartis
Phase 2 Completed
NCT03007979 2024-03-20
Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
Washington University School of Medicine
Phase 2 Completed
NCT00295646 2024-03-15
Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid
Austrian Breast & Colorectal Cancer Study Group
Phase 3 Completed
NCT02278120 2024-03-12
MONALEESA-7
Novartis
Phase 3 Completed
NCT02941926 2023-10-24
COMPLEEMENT-1
Novartis
Phase 3 Completed
NCT02058706 2023-05-10
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT00432172 2023-04-03
Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients
Spanish Breast Cancer Research Group
Phase 2 Completed
NCT00004124 2022-12-30
S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer
SWOG Cancer Research Network
Phase 3 Completed
NCT00005044 2022-06-15
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT02586675 2022-01-21
TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT03096847 2021-10-11
Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer
Novartis
Phase 3 Completed
NCT02518191 2021-06-11
Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Phase 3 Completed
NCT02059213 2020-09-16
A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT01790126 2020-03-11
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Aragon Pharmaceuticals, Inc.
Phase 2 Completed
NCT00068601 2019-12-30
S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
SWOG Cancer Research Network
Phase 3 Completed
NCT00186121 2019-10-07
Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women
Stanford University
Phase 2 Completed
NCT00669162 2019-07-24
Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer
University of Kansas Medical Center
Phase 1/2 Completed
NCT01073865 2018-12-12
Study to Compare Zoladexâ„¢ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer
AstraZeneca
Phase 3 Completed
NCT00298155 2018-08-09
TAPS
University of Washington
Phase 2 Completed
NCT00283803 2018-08-07
Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer
University of Washington
Phase 2 Completed
NCT00002597 2018-06-14
Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00004635 2018-05-22
Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 3 Completed
NCT01496131 2018-03-09
Tecemotide (L-BLP25) in Prostate Cancer
EMD Serono
Phase 2 Completed
NCT01120236 2018-02-26
Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00589472 2017-10-06
TARGET
National Cancer Institute (NCI)
Phase 2 Completed
NCT01023061 2017-06-06
RAD1
University of Washington
Phase 2 Completed
NCT00225420 2017-06-01
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Completed
NCT00658697 2017-05-25
Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00170157 2017-05-15
Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
Mayo Clinic
Phase 2 Completed
NCT00002651 2017-04-17
SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer
SWOG Cancer Research Network
Phase 3 Completed
NCT01750398 2016-12-05
BAT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00081159 2016-11-10
Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01076335 2016-09-19
Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00016913 2016-07-06
Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00586898 2016-03-25
Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00454571 2016-02-10
Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00108732 2015-06-30
A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00500110 2015-04-28
Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00946920 2014-06-02
A Trial of Degarelix in Patients With Prostate Cancer
Ferring Pharmaceuticals
Phase 3 Completed
NCT01088529 2014-05-15
Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer
Cougar Biotechnology, Inc.
Phase 2 Completed
NCT01250717 2014-02-04
Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Completed